Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
43.67
+0.58 (1.35%)
At close: Jun 27, 2025, 4:00 PM
43.51
-0.16 (-0.37%)
After-hours: Jun 27, 2025, 4:45 PM EDT
Exelixis Revenue
Exelixis had revenue of $555.45M in the quarter ending March 31, 2025, with 30.62% growth. This brings the company's revenue in the last twelve months to $2.30B, up 24.49% year-over-year. In the year 2024, Exelixis had annual revenue of $2.17B with 18.49% growth.
Revenue (ttm)
$2.30B
Revenue Growth
+24.49%
P/S Ratio
5.04
Revenue / Employee
$2,004,291
Employees
1,147
Market Cap
11.91B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.17B | 338.49M | 18.49% |
Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
EXEL News
- 5 days ago - Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment - Seeking Alpha
- 5 days ago - Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars - Benzinga
- 5 days ago - Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer - Business Wire
- 8 days ago - Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire
- 5 weeks ago - Product Performance, Big Money Lift Exelixis - FXEmpire
- 5 weeks ago - Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025 - Business Wire
- 5 weeks ago - Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June - Business Wire
- 6 weeks ago - Exelixis: A Notable Quarter - Seeking Alpha